AIMS: To identify prospectively a safe therapeutic window for administration of a novel oral transforming growth factor β (TGF-β) inhibitor, LY2157299 monohydrate, based on a pharmacokinetic/pharmacodynamic (PK/PD) model. Simulations of population plasma exposures and biomarker responses in tumour were performed for future trials of LY2157299 in glioblastoma and other cancer populations. METHODS: The model was updated after completion of each cohort during the first-in-human dose (FHD) study. The flexible design allowed continuous assessment of PK variability by recruiting the required number of patients in each cohort. Based on 30% inhibition of TGF-β RI kinase phosphorylates (pSMAD), biologically effective exposures were anticipated to be reached from 160 mg onwards. The therapeutic window was predicted, based on animal data, to be between 160 and 360 mg. RESULTS: No medically significant safety issues were observed and no dose limiting toxicities were established in this study. Observed plasma exposures (medians 2.43 to 3.7 mg l⁻¹ h, respectively) with doses of 160 mg to 300 mg were within the predicted therapeutic window. Responses, based on the MacDonald criteria, were observed in these patients. CONCLUSIONS: A therapeutic window for the clinical investigation of LY2157299 in cancer patients was defined using a targeted PK/PD approach, which integrated translational biomarkers and preclinical toxicity. The study supports using a therapeutic window based on a PK/PD model in early oncology development.
AIMS: To identify prospectively a safe therapeutic window for administration of a novel oral transforming growth factor β (TGF-β) inhibitor, LY2157299 monohydrate, based on a pharmacokinetic/pharmacodynamic (PK/PD) model. Simulations of population plasma exposures and biomarker responses in tumour were performed for future trials of LY2157299 in glioblastoma and other cancer populations. METHODS: The model was updated after completion of each cohort during the first-in-human dose (FHD) study. The flexible design allowed continuous assessment of PK variability by recruiting the required number of patients in each cohort. Based on 30% inhibition of TGF-β RI kinase phosphorylates (pSMAD), biologically effective exposures were anticipated to be reached from 160 mg onwards. The therapeutic window was predicted, based on animal data, to be between 160 and 360 mg. RESULTS: No medically significant safety issues were observed and no dose limiting toxicities were established in this study. Observed plasma exposures (medians 2.43 to 3.7 mg l⁻¹ h, respectively) with doses of 160 mg to 300 mg were within the predicted therapeutic window. Responses, based on the MacDonald criteria, were observed in these patients. CONCLUSIONS: A therapeutic window for the clinical investigation of LY2157299 in cancerpatients was defined using a targeted PK/PD approach, which integrated translational biomarkers and preclinical toxicity. The study supports using a therapeutic window based on a PK/PD model in early oncology development.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Mark J Anderton; Howard R Mellor; Alex Bell; Claire Sadler; Martin Pass; Steve Powell; Samantha J Steele; Ruth R A Roberts; Annabelle Heier Journal: Toxicol Pathol Date: 2011-08-22 Impact factor: 1.902
Authors: Monica Simeoni; Paolo Magni; Cristiano Cammia; Giuseppe De Nicolao; Valter Croci; Enrico Pesenti; Massimiliano Germani; Italo Poggesi; Maurizio Rocchetti Journal: Cancer Res Date: 2004-02-01 Impact factor: 12.701
Authors: J Scott Sawyer; Bryan D Anderson; Douglas W Beight; Robert M Campbell; Michael L Jones; David K Herron; John W Lampe; Jefferson R McCowan; William T McMillen; Nicholas Mort; Stephen Parsons; Edward C R Smith; Michal Vieth; Leonard C Weir; Lei Yan; Faming Zhang; Jonathan M Yingling Journal: J Med Chem Date: 2003-09-11 Impact factor: 7.446
Authors: Alba A Brandes; Antoine F Carpentier; Santosh Kesari; Juan M Sepulveda-Sanchez; Helen R Wheeler; Olivier Chinot; Lawrence Cher; Joachim P Steinbach; David Capper; Pol Specenier; Jordi Rodon; Ann Cleverly; Claire Smith; Ivelina Gueorguieva; Colin Miles; Susan C Guba; Durisala Desaiah; Michael M Lahn; Wolfgang Wick Journal: Neuro Oncol Date: 2016-02-21 Impact factor: 12.300
Authors: Theerut Luangmonkong; Su Suriguga; Emilia Bigaeva; Miriam Boersema; Dorenda Oosterhuis; Koert P de Jong; Detlef Schuppan; Henricus A M Mutsaers; Peter Olinga Journal: Br J Pharmacol Date: 2017-08-11 Impact factor: 8.739
Authors: Juan Sepulveda-Sanchez; Ana Ramos; Amaya Hilario; Guillermo DE Velasco; Daniel Castellano; Marta Garcia DE LA Torre; Jordi Rodon; Michael F Lahn Journal: Oncol Lett Date: 2015-04-08 Impact factor: 2.967
Authors: Yanxia Zhao; Jinghong Cao; Alexander Melamed; Michael Worley; Allison Gockley; Dennis Jones; Hadi T Nia; Yanling Zhang; Triantafyllos Stylianopoulos; Ashwin S Kumar; Fotios Mpekris; Meenal Datta; Yao Sun; Limeng Wu; Xing Gao; Oladapo Yeku; Marcela G Del Carmen; David R Spriggs; Rakesh K Jain; Lei Xu Journal: Proc Natl Acad Sci U S A Date: 2019-01-18 Impact factor: 11.205
Authors: Hung C Tran; Zesheng Wan; Michael A Sheard; Jianping Sun; Jeremy R Jackson; Jemily Malvar; Yibing Xu; Larry Wang; Richard Sposto; Eugene S Kim; Shahab Asgharzadeh; Robert C Seeger Journal: Clin Cancer Res Date: 2016-10-10 Impact factor: 12.531